1. Home
  2. NAZ vs SGMT Comparison

NAZ vs SGMT Comparison

Compare NAZ & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Arizona Quality Municipal Income Fund

NAZ

Nuveen Arizona Quality Municipal Income Fund

HOLD

Current Price

$12.80

Market Cap

156.2M

Sector

Finance

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.20

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAZ
SGMT
Founded
1992
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
156.2M
169.4M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
NAZ
SGMT
Price
$12.80
$7.20
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$26.13
AVG Volume (30 Days)
18.6K
886.5K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
3.69%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.40
$3.44
52 Week High
$13.00
$11.41

Technical Indicators

Market Signals
Indicator
NAZ
SGMT
Relative Strength Index (RSI) 54.94 52.93
Support Level $11.72 $7.09
Resistance Level $12.94 $7.86
Average True Range (ATR) 0.16 0.41
MACD -0.01 -0.07
Stochastic Oscillator 57.88 52.70

Price Performance

Historical Comparison
NAZ
SGMT

About NAZ Nuveen Arizona Quality Municipal Income Fund

Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: